Complexation of VEGF with bevacizumab decreases VEGF clearance in rats.
Hsei
Vanessa
V
hsei@gene.com
Deguzman
Geralyn G
GG
Nixon
Alison
A
Gaudreault
Jacques
J
D043925:Angiogenesis Inducing Agents / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000378:metabolism*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002626:Chemistry, Pharmaceutical; D005260:Female; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D042461:Vascular Endothelial Growth Factor A
D043925:Angiogenesis Inducing Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab